{"id":85832,"date":"2026-09-24T05:09:00","date_gmt":"2026-09-24T05:09:00","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/?p=85832"},"modified":"2026-09-27T01:26:37","modified_gmt":"2026-09-27T01:26:37","slug":"innocare-announces-strategic-research-collaboration-and-license-agreement-with-lilly-to-develop-new-medicines","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/innocare-announces-strategic-research-collaboration-and-license-agreement-with-lilly-to-develop-new-medicines\/","title":{"rendered":"InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines"},"content":{"rendered":"<p>BEIJING, Sept.  24, 2026  (GLOBE NEWSWIRE) &#8212; InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Company has entered into a strategic research collaboration and license agreement with Eli Lilly and Company (\u201cLilly\u201d) to develop new medicines.<\/p>\n<p>InnoCare will leverage its proprietary drug discovery platform and extensive research experience to discover and advance compounds against up to five targets to address critical unmet medical needs.<\/p>\n<p>\u201cWe are excited to leverage our R&amp;D platform to collaborate with a global pharmaceutical leader like Lilly,\u201d said Dr. Jasmine Cui, the Co-founder, Chairwoman and CEO of InnoCare. \u201cWe are dedicated to expanding our partnership and innovation footprint.\u201d<\/p>\n<p>Under the terms of the agreement, InnoCare will be eligible to receive up to $100 million in upfront and near-term payments, and up to approximately $3.25 billion in development and commercial milestone payments. In addition, InnoCare will be eligible to receive single-digit tiered royalties based on annual net product sales.<\/p>\n<p><strong>About InnoCare Pharma<\/strong><\/p>\n<p>InnoCare (HKEX: 09969; SSE: 688428) is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing innovative drugs for the treatment of cancers and autoimmune diseases, two therapeutic areas with unmet medical needs worldwide. InnoCare has established comprehensive innovation platforms for drug discovery. To date, the Company has developed a robust product pipeline comprising three approved drugs (orelabrutinib, tafasitamab and zurletrectinib), more than ten innovative drug candidates in clinical development, and multiple programs in preclinical stages. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong SAR, and the United States. For more information about InnoCare, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=glGIUMhUO5C692ohI4icqata5OtqcUX-mpzL4RO5sk8ceK5hSTDTvdF8cuPtxm6eeH7_CY7l8hmd9zB8Zqyl2PoMfuTjAoyYE8MHR67SLVBxYhmM_GNrD8TJdRPXS03M\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.innocarepharma.com\/en<\/a> and follow us on LinkedIn.<\/p>\n<p><strong>Forward-Looking Statements<\/strong><br \/>This release contains certain forward-looking statements. All statements, other than statements of fact, could be considered forward-looking statements, meaning statements regarding actions, events, or developments that we or our management intend, expect, project, believe, or anticipate will or may occur in the future. These statements are based on assumptions and estimates made by our management in light of their experience and perception of historical trends, current conditions, expected future developments, and other relevant factors. Forward-looking statements are not guarantees of future performance, and actual results, developments, and business decisions may differ materially from those contemplated by these forward-looking statements. Our forward-looking statements are subject to a number of risks and uncertainties that could affect our near- and long-term performance.<\/p>\n<p><strong>Cautionary Statement<\/strong><br \/>The payments in this research collaboration and license agreement are subject to certain conditions. There is still uncertainty regarding the final payment.<\/p>\n<table style=\"border-collapse: collapse; width:100.006%; border-collapse:collapse ;\">\n<tr>\n<td style=\"width:49.753%;\">Contact<\/td>\n<td style=\"width:49.753%;\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:49.753%;\"><strong>Media<\/strong><\/td>\n<td style=\"width:49.753%;\"><strong>Investors<\/strong><\/td>\n<\/tr>\n<tr>\n<td style=\"width:49.753%;\">Chunhua Lu<\/td>\n<td style=\"width:49.753%;\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:49.753%;\">86-10-66609879<br \/><a href=\"mailto:chunhua.lu@innocarepharma.com\" rel=\"nofollow\" target=\"_blank\" title=\"chunhua.lu@innocarepharma.com\">chunhua.lu@innocarepharma.com<\/a><\/td>\n<td style=\"width:49.753%;\">86-10-66609999<br \/><a href=\"mailto:ir@innocarepharma.com\" rel=\"nofollow\" target=\"_blank\" title=\"ir@innocarepharma.com\">ir@innocarepharma.com<\/a><\/td>\n<\/tr>\n<\/table>\n<p><\/p>\n<p><img alt=\"\" src='https:\/\/ml.globenewswire.com\/media\/ZTUwZjljNzQtMGUyZi00Y2I1LWFlMTgtZjg3OWZhYWE4MjA2LTEzMDQxMzAtMjAyNi0wOS0yNC1lbg==\/tiny\/Beijing-InnoCare-Pharma-Tech-C.png' referrerpolicy='no-referrer-when-downgrade' \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BEIJING, Sept. 24, 2026 (GLOBE NEWSWIRE) &#8212; InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Company has entered into a strategic research collaboration and license agreement with Eli Lilly and Company (\u201cLilly\u201d) to develop new medicines. InnoCare will leverage its [&#8230;]\n","protected":false},"author":1,"featured_media":85254,"comment_status":"open","ping_status":"closed","sticky":false,"template":"Default","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-85832","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globe-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/innocare-announces-strategic-research-collaboration-and-license-agreement-with-lilly-to-develop-new-medicines\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines\" \/>\n<meta property=\"og:description\" content=\"BEIJING, Sept. 24, 2026 (GLOBE NEWSWIRE) &#8212; InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treat\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/innocare-announces-strategic-research-collaboration-and-license-agreement-with-lilly-to-develop-new-medicines\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-24T05:09:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-27T01:26:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/09\/innocare-announces-strategic-research-collaboration-and-license-agreement-with-lilly-to-develop-new-medicines.gif\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/gif\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/innocare-announces-strategic-research-collaboration-and-license-agreement-with-lilly-to-develop-new-medicines\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/innocare-announces-strategic-research-collaboration-and-license-agreement-with-lilly-to-develop-new-medicines\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines\",\"datePublished\":\"2026-09-24T05:09:00+00:00\",\"dateModified\":\"2026-09-27T01:26:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/innocare-announces-strategic-research-collaboration-and-license-agreement-with-lilly-to-develop-new-medicines\/\"},\"wordCount\":448,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Globe Newswire\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/innocare-announces-strategic-research-collaboration-and-license-agreement-with-lilly-to-develop-new-medicines\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/innocare-announces-strategic-research-collaboration-and-license-agreement-with-lilly-to-develop-new-medicines\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/innocare-announces-strategic-research-collaboration-and-license-agreement-with-lilly-to-develop-new-medicines\/\",\"name\":\"InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-09-24T05:09:00+00:00\",\"dateModified\":\"2026-09-27T01:26:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/innocare-announces-strategic-research-collaboration-and-license-agreement-with-lilly-to-develop-new-medicines\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/innocare-announces-strategic-research-collaboration-and-license-agreement-with-lilly-to-develop-new-medicines\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/innocare-announces-strategic-research-collaboration-and-license-agreement-with-lilly-to-develop-new-medicines\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/innocare-announces-strategic-research-collaboration-and-license-agreement-with-lilly-to-develop-new-medicines\/","og_locale":"en_US","og_type":"article","og_title":"InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines","og_description":"BEIJING, Sept. 24, 2026 (GLOBE NEWSWIRE) &#8212; InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treat","og_url":"https:\/\/english.saigonbiz.com\/vn\/innocare-announces-strategic-research-collaboration-and-license-agreement-with-lilly-to-develop-new-medicines\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-09-24T05:09:00+00:00","article_modified_time":"2026-09-27T01:26:37+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/09\/innocare-announces-strategic-research-collaboration-and-license-agreement-with-lilly-to-develop-new-medicines.gif","type":"image\/gif"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/innocare-announces-strategic-research-collaboration-and-license-agreement-with-lilly-to-develop-new-medicines\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/innocare-announces-strategic-research-collaboration-and-license-agreement-with-lilly-to-develop-new-medicines\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines","datePublished":"2026-09-24T05:09:00+00:00","dateModified":"2026-09-27T01:26:37+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/innocare-announces-strategic-research-collaboration-and-license-agreement-with-lilly-to-develop-new-medicines\/"},"wordCount":448,"commentCount":0,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Globe Newswire"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/english.saigonbiz.com\/vn\/innocare-announces-strategic-research-collaboration-and-license-agreement-with-lilly-to-develop-new-medicines\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/innocare-announces-strategic-research-collaboration-and-license-agreement-with-lilly-to-develop-new-medicines\/","url":"https:\/\/english.saigonbiz.com\/vn\/innocare-announces-strategic-research-collaboration-and-license-agreement-with-lilly-to-develop-new-medicines\/","name":"InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-09-24T05:09:00+00:00","dateModified":"2026-09-27T01:26:37+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/innocare-announces-strategic-research-collaboration-and-license-agreement-with-lilly-to-develop-new-medicines\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/innocare-announces-strategic-research-collaboration-and-license-agreement-with-lilly-to-develop-new-medicines\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/innocare-announces-strategic-research-collaboration-and-license-agreement-with-lilly-to-develop-new-medicines\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/85832","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=85832"}],"version-history":[{"count":1,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/85832\/revisions"}],"predecessor-version":[{"id":85834,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/85832\/revisions\/85834"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/85254"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=85832"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=85832"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=85832"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}